INNOVENT BIO Shares Surge Over 5% on Strong Earnings and First Annual Profit

Stock News03-27

INNOVENT BIO (01801) saw its shares rise more than 5% in morning trading. At the time of writing, the stock was up 5.48%, trading at HKD 83.75 with a turnover of HKD 474 million. The movement follows the company's release of its annual results, which showed total revenue of RMB 13.0415 billion, a year-on-year increase of 38.4%. The company achieved its first full-year profit, with IFRS net profit reaching RMB 814 million, a significant improvement compared to a loss of RMB 94.63 million in 2024. In the financial review, product revenue was reported at RMB 11.896 billion, up 44.6% year-on-year, primarily driven by its leading position in oncology and the rapid expansion of its comprehensive product portfolio. Although royalty income decreased to RMB 957 million (compared to RMB 1.1 billion in 2024), strong overall revenue growth still contributed to enhanced profitability. Non-IFRS net profit surged to RMB 1.723 billion, an increase of 419.6% compared to the previous year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment